Judgment of the National Green Tribunal in the matter of Shalbjit Singh Vs Punjab State Pollution Control Board & Others dated 21/11/2024. A letter petition dated November 5, 2022 was sent by Shalabhjeet Singh, resident of village Haibatpur, tehsil Derabassi, district SAS Nagar, Mohali complaining that M/s Nectar Life Sciences …
Aggressive marketing initiatives by Pfizer Inc may reduce Ranbaxy Laboratories’ earnings from the scheduled launch of its lowcost version of Lipitor, the world’s largest selling drug, in the US by the month end. The world’s largest drugmaker earns around $6 billion from Lipitor sales in the US and it has …
The country’s drug regulator has given conditional market approval for Ranbaxy Laboratories’ anti-malaria drug, paving the way for the launch of the country’s first privately-developed medicine and ending more than a decade of failures or near misses for India’s drug makers While the domestic drug industry has been successful in …
Pfizer Inc and Dr Reddy’s Laboratories have settled a patent infringement suit related to the Indian drug maker’s launch of a generic version of the blockbuster drug, Lipitor, in the US. Pfizer’s Lipitor is the world’s largest-selling drug, which generated about $7 billion in sales last year in the US …
Daiichi Sankyo Company and Ranbaxy Laboratories Ltd on Wednesday announced an initiative to sponsor mobile healthcare field clinics in India, Cameroon and Tanzania as part of their global social contribution activities. The initiative will be implemented in India through the Ranbaxy Community Health Care Society, a non-profit organisation established by …
Drug major Ranbaxy On Wednesday said it will spend nearly ¥200 million (over Rs 10 crore) along with parent company Daiichi Sankyo over the next five years to sponsor mobile healthcare field clinics in India, Cameroon and Tanzania. The services will be provided in the fields of basic healthcare, immunisation, …
No major deficiency found during inspection of Ranbaxy, Orchid, Emcure, Nectar & Ind Swift Facilities The US drug regulator has inspected manufacturing plants of at least half a dozen Indian drugmakers in the last few weeks, raising hopes among some of these companies that they will shortly be able to …
Co may resume supplies to the US nearly 3 years after they were halted from its 2 plants American drug authorities have started inspecting Ranbaxy Laboratories
Global drugmakers have started launching generic or low-priced version of popular medicines and have slashed prices of their existing products to increase market share in India, taking on local competitors in their own game. French drugmaker Sanofi Aventis has launched a range of generic drugs, some at half the price …
Dr S. Chandrashekar, a Director-grade scientist at the Indian Institute of Chemical Technology (IICT) here was selected for the Ranbaxy Research Award for the year 2009. Dr Chandrashekar was chosen for his exemplary work in the area of pharmaceutical sciences, according to a release.
LUPIN Limited and Ranbaxy Laboratories along with its parent company Daiichi Sankyo have slapped patent infringement charges against each other to stop one another from launching low-cost versions of their respective original drugs in the US. Last Wednesday, Lupin sued Ranbaxy after the latter sought American drug regulator
Indian Company To Become Pure Generics Drugmaker; To Retain Research Activity For Anti-Malarial Drug RANBAXY Laboratories has transferred its research division for new drugs to Japan
RANBAXY Laboratories on Monday announced it has settled a patent dispute with Takeda Pharmaceutical allowing the Gurgaon-based drugmaker to launch its generic tablets of Takeda
Deal Could Be Aimed At Getting Access To Technology Or Manufacturing Platform Khomba Singh NEW DELHI RANBAXY Laboratories has started discussions to buy a privately held Bangalore-based vaccine company, two persons familiar with the development said. While the identity of the company could not be ascertained one of persons said …
DRL, Cipla Among Cos Found Involved In Overcharging By Drug Price Regulator DRUG manufacturing companies such as Cipla, Ranbaxy, Johnson & Johnson and Dr Reddy
